Nationwide cardiovascular risk categorization: applying the European Society of Cardiology guidelines to the Swedish National Diabetes Register
Authors' conclusion
This analysis highlights differences between previous prescribing practices in Sweden and the 2021 ESC guidelines
Study context
- Population
- Patients with T2DM aged 18–90 years in the Swedish National Diabetes Register not receiving cardiovascular (CV)-protective glucose-lowering medication in 2017129,512 at very high cardiovascular disease (CVD) risk
- Participants
- 320,028 patients
- Outcome
- MACE:
- CV death
- Non-fatal stroke
- Non-fatal MI
- Follow-up
- 2017
Methodological detailsnationwide
- Nationwide
Main finding
As reported in the abstract
MACE incidence
Very high CVD risk (European Society of Cardiology (ESC) criteria)
75.4 events/1000 person-years
Atherosclerotic CVD (ASCVD) with elevated HbA1c (>9%)
136.5 events/1000 person-years
ASCVD without elevated HbA1c
90.8 events/1000 person-years
Observational data: associations, not effects.
Further findings
Estimated MACE avoided with semaglutide (very high CVD risk and ASCVD) · 2017
- MACE that may have been avoided
- 803
- Estimated
Original publication
Nationwide cardiovascular risk categorization: applying the European Society of Cardiology guidelines to the Swedish National Diabetes Register. Eur J Prev Cardiol. Published 26 December 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →